VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: VLAD who wrote (6764)	4/9/1998 8:07:00 PM
From: av ram	Read Replies (1) of 23519

Following came in Dow Jones News wire, I think at after the close. Mention of MUSE. Sales Of Impotence Drugs Expected To Continue To Rise In 1998 Dow Jones Online News, Thursday, April 09, 1998 at 17:48 WASHINGTON -(Dow Jones)- Industry watchers expect sales of impotence drugs to continue to soar. According to IMS America, a company that follows pharmaceuticals, the "sexual disorder" market had sales of $156.7 million off 1.2 million prescriptions in 1997. Sales nearly quadrupled over 1996's $35.1 million. IMS said Thursday it expects big numbers for 1998 with last month's approval of Pfizer Inc.'s (PFE) drug Viagra, the first pill for the disorder. Other impotence drugs are injected. Vivus Inc. (VVUS) led last year with sales of $108.3 million for its two products Muse and Actis. Pharmacia & Upjohn Inc.'s (PNU) Caverject had $47 million in sales and Schwartz Pharma's Edex, which hit the market late last year, had $1.4 million in sales. -Otesa Middleton; 202-862-6654 Copyright (c) 1998 Dow Jones & Company, Inc. All Rights Reserved.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next